Impulse Qingdao Health Tech Co Ltd

The company maintains a relatively strong liquidity position, with a current ratio of 2.59, indicating that it has more than enough current assets to cover its short-term liabilities. However, its liquidity is rated as medium due to a negative net cash position after subtracting total debt, which could pose challenges in the event of unexpected cash flow disruptions. The debt-to-equity ratio of 0.47 suggests a moderate level of leverage, with long-term debt accounting for a significant portion of its liabilities.

Profitability metrics show a return on equity of 2.27% and a return on assets of 1.31%, both of which are below the industry median for recreational products. This indicates that the company is generating relatively modest returns compared to its peers. The gross profit margin of 31.1% is in line with industry norms, but the operating margin of 13.0% is slightly below average, suggesting potential inefficiencies in cost management or pricing power.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. No material revenue is attributed to international markets, which limits the company's ability to hedge against domestic economic risks.

Looking ahead, the company is expected to see a significant increase in revenue, with analysts forecasting a jump from 333.4 million CNY to 1.22 billion CNY in the next fiscal year. This represents a 266% year-over-year growth, driven by anticipated market expansion and product innovation. However, the company's capital expenditures are negative, indicating asset disposals or a reduction in investment, which may signal a strategic shift or financial constraints.

The company faces moderate liquidity risk due to its negative net cash position and a medium risk of dilution, although the probability of near-term dilution is low. No recent equity issuance or ATM/shelf registration has been disclosed, and the company has not issued new shares in the past year. The risk assessment also highlights the need for careful monitoring of cash flow and debt management to avoid liquidity stress.

Recent events include the release of the latest financial report, which shows a net income of 37.3 million CNY and an operating income of 43.3 million CNY. The company has not disclosed any major legal or regulatory issues, but it has noted the importance of maintaining product quality and customer satisfaction in its investor relations communications.

Impulse Qingdao Health Tech Co Ltd (002899.SZ) has undergone a significant reclassification in its business taxonomy, shifting its activity designation to "Recreational Products" and its economic sector to "Consumer Cyclicals." This change represents a medium-severity update to the company's profile, moving from an undefined classification to a specific alignment within the consumer discretionary space. The reclassification suggests a strategic or operational pivot toward consumer-facing recreational goods, distinguishing the firm from its previous or implied health-tech-centric identity. By aligning with the Consumer Cyclicals sector, the company’s performance metrics and valuation benchmarks are now more likely to be compared against peers in the recreational products industry rather than traditional healthcare or technology firms. In terms of risk assessment, the company has been assigned a "low" dilution risk and a "medium" liquidity risk. These new risk parameters provide investors with a clearer picture of the capital structure stability and trading dynamics, indicating that while share dilution is not a primary concern, liquidity conditions warrant moderate attention. Currently, the company shows no recorded analyst coverage, index memberships, or top holder data in the available profile. This lack of external financial tracking metrics means that the recent taxonomy and risk updates serve as the primary structural changes for investors to consider when evaluating Impulse Qingdao Health Tech’s market positioning.

Revenue grew 31.3% year-over-year to CNY 1.18 billion, demonstrating strong top-line expansion momentum.

Free cash flow turned positive to CNY 49.9 million, reversing previous years of negative cash generation.

Cash conversion ratio of 0.73 exceeds the cohort median of 0.68, indicating efficient earnings quality.

The company faces high credit risk, posing significant potential financial stability concerns for investors.

Long-term debt increased to CNY 634 million, maintaining a substantial leverage burden on the balance sheet.

Revenue ¥1.21B, +35,6% YoY; Operating income +21,8% YoY.

• ▍Revenue ¥1.21B, +35,6% YoY
• ▍Operating income +21,8% YoY
• ▍Net income +23,8% YoY
• ▍Free cash flow +66,5% YoY
• ▍Net margin 9.0%

Revenue ¥864.4M; Operating income ¥39.9M.

• ▍Revenue ¥864.4M
• ▍Operating income ¥39.9M
• ▍Net margin 2.0%